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Our understanding of biological mechanisms 
operating at articular and extra- articular sites 
in individuals ‘at risk’ of rheumatoid arthritis 
(RA) has increased significantly over recent 
years.1 In parallel, there has been significant 
progress in the prediction of RA develop-
ment in those at risk.2 This has opened up an 
agenda for research on possibilities for inter-
vention in pre- RA phases, and opportunities 
for both primary and secondary prevention 
have been identified.3–5
Intervention at the very earliest stages of 
disease development could, in theory, control 
symptoms such as arthralgia and fatigue that 
often precede the development of clinical 
arthritis,6 delay the onset of RA, reduce the 
likelihood of RA developing and/or reduce 
the severity of RA if it were to develop. While the 
evidence base to support such strategies is in 
its infancy, B- cell depletion, with a single infu-
sion of 1000 mg of rituximab, has been shown 
to significantly delay the onset of RA in indi-
viduals with autoantibody- positive arthralgia 
and either an inflammatory response as 
measured by C- reactive protein or subclinical 
synovitis on imaging.7 Similarly, the impact of 
time- limited courses of other immunomod-
ulatory therapies, including abatacept8 and 
hydroxychloroquine,9 on arthritis and RA 
development is being assessed in other at- risk 
groups. Results of these studies,8 9 where the 
intervention is given for 12 months, and 
other studies, where interventions are given 
for different but nevertheless time- limited 
durations, are awaited with interest. Preven-
tive strategies are also under investigation in 
other chronic autoimmune conditions. For 
example, an anti- CD3 antibody has recently 
been shown to significantly delay progression 
to type 1 diabetes in non- diabetic relatives of 
patients identified as being at high risk on the 
basis of the presence of diabetes- related auto-
antibodies and other risk factors.10
To have clinical impact, therapeutic 
approaches identified as being effective in 
reducing the risk of RA need to be acceptable 
to those at risk. Previous qualitative research 
has identified that individuals at risk of RA 
have concerns about taking ‘preventive’ 
medicines.11 In this issue of RMD Open, van 
Boheemen et al2 report on the perspectives 
of individuals who had declined participa-
tion in, and also who had participated in, one 
of the two RA prevention trials: the STAtins 
to Prevent Rheumatoid Arthritis trial (RMD 
open to insert Ref) and the Arthritis Preven-
tion In the Pre- clinical Phase of RA with 
Abatacept trial.8 Challenges to participant 
recruitment in trials of patients with seropos-
itive arthralgia raise some important issues 
for the rheumatology research community to 
consider and reflect the importance of under-
standing the preferences of at- risk individuals 
about benefits and risks of interventions in 
relation to the disease they are at risk of.12
Public perceptions about RA are often 
inaccurate: many do not perceive RA to be a 
serious disease, and some view it as an inevi-
table consequence of ageing.13 14 Individuals 
with these views may be less likely to accept 
preventive therapeutic interventions—this 
was certainly a theme identified by van 
Boheemen et al2. Positive views about RA 
prediction and prevention are often associ-
ated with misperceptions around what being 
at ‘high risk’ means (eg, some interpret this 
to mean that they will definitely develop RA) 
and the likely benefit of ‘preventive’ therapy 
(eg, for some this means the therapy will defi-
nitely prevent them from developing RA).15–17 
The development of effective communication 
tools around predictive testing, preventive 
interventions and RA itself is therefore essen-
tial to facilitate informed decision- making. 
Although predictive algorithms exist, they 
do not fully address issues around the time 
course of RA development or the likely 
severity of RA after it has developed, which are 
key considerations for decision- making about 
preventive therapy. Further research to facil-
itate comprehensive risk assessment for RA 
is an essential precursor to the development 
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of effective informational resources for individuals for 
whom preventive treatment may be appropriate.
Non- pharmacological interventions are preferred 
by some at- risk individuals, especially for those without 
symptoms (eg, autoantibody- positive individuals and 
those with genetic risk factors)11 15–19 van Boheemen et 
al2. Initial evidence suggests that personalised risk infor-
mation about RA has a positive impact on behavioural 
intentions and risk- reducing behaviour20 while providing 
reassurance to recipients.21 Although several ongoing 
studies are investigating pharmacological interventions 
to prevent arthritis development, no interventional trials 
of promising behavioural interventions, particularly 
smoking cessation,22 23 to reduce risk of RA development 
and progression have been published. Investigation in 
this area is needed.
Preventive therapies for other conditions are well 
established in routine clinical practice; statins and anti-
hypertensive medications are widely prescribed to reduce 
the risk of ischaemic heart disease and bisphosphonates 
to reduce the risk of fracture. Many entirely asymptom-
atic individuals with conditions such as hypercholes-
terolaemia, hypertension and osteoporosis accept such 
pharmacological therapies. Indeed, for these conditions, 
long- term, often lifelong, preventive treatment is both 
required and often accepted. As yet, no pharmacolog-
ical treatments have been shown to reduce the risk of RA 
development in the medium to long term. However, this 
remains an active and important area of research. We 
need to learn from experiences in other chronic diseases 
and address the barriers identified by van Boheemen et 
al2 that hinder the efficient development of preventive 
strategies for the management of RA. Endeavouring to 
overcome such barriers is likely to be worthwhile, given 
that a ‘preventive’ approach in RA has clear potential to 
reduce pain and disability as well as societal costs resulting 
from lost productivity and healthcare usage at huge scale.
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